The original success of Sildenafil undeniably reshaped the medication landscape, but investing in companies heavily reliant on generic versions presents a complex picture. Although early earnings were impressive, the end of patents and the emergence of discounted alternatives have weakened market share. Therefore, a thorough evaluation of present i